A way to understand idiopathic senescence and apoptosis in primary glioblastoma cells – possible approaches to circumvent these phenomena

Table 1 Sample description and molecular alterations detected in all analyzed tumor specimens and corresponding cultures

	Patient data	MLPA		Other molecular analyses IDH1, TP53 (seq) and EGFR (FISH, RT PCR) status	In vitro culturing		Immortalization	In vivo culturing
	Sex	Gain	Del		Monolayer	NSC-like	Immortalization	In vivo culturing
GB1	M	EGFR, MDM4, PDGFRA, KIT, KDR, MET	CDKN2A, CDKN2B, AMER1, RET, PTEN*	EGFRvIII amplification	Yes	N/A	N/A	N/A
GB2	F	EGFR, MDM, MET, AURKA, BRAF	CDKN2A, PTEN	IDH1 – NA TP53 – NA EGFRvIII amplification in single cells	Yes	N/A	N/A	N/A
GB3	M	EGFR, MET, PTEN	CDKN2A*	IDH1 p.R132H TP53 p.P190L EGFRvIII amplification	Yes	N/A	tested	N/A
GB4	F	CCND1, BRAF, AURKA	CDKN2A	IDH1 p.R132H	Yes	N/A	N/A	N/A
GB5	F	PDGFRA, KIT, KDR, NFKB1, CDK4	CDKN2A, CDKN2B, MDM2	–	Yes	N/A	N/A	N/A
GB6	F	NFKB1, PTEN	MDM2	TP53 p.P190L	Yes	Yes	tested	Yes
GB7 stabilized	F	EGFR, NFKB1A	MDM2*	TP53 p.Y205H polysomy, EGFRvIII amplification in single cells	stabilized⁺	stabilized⁺	tested	N/A
GB8	M	EGFR, NFKB1A, PTEN	MDM2*	EGFRvIII amplification in single cells	Yes	Yes	tested	Yes
GB9	M	EGFR, MDM2, CDK4	CDKN2A, PTEN*	TP53 p.Y234* EGFRvIII amplification in single cells	Yes	Yes	tested	Yes
GB10 stabilized	M	EGFR, CDK4, MDM2, BRAF, PDGFRA	RET*	EGFRvIII amplification	stabilized⁺	stabilized⁺	N/A	N/A

F Female, M Male; *deletion of one allele; “-”not detected; N/A Not analyzed; seq – Sanger sequencing/IHC for IDH1 codon 132; TP53 exons 4–8; ⁺tumors that stabilize in NSC-like conditions tend to stabilize irrespective to culture approach; detailed data shown in Additional file 3: Table S3

ISSN: 1471-2407